Your session is about to expire
← Back to Search
Polyphenols
Resveratrol, Quercetin, Curcumin (RQC) for Age-Related Macular Degeneration
Phase 2
Waitlist Available
Led By Paul A Knepper, MD, PhD
Research Sponsored by Paul A Knepper, MD PhD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights
Summary
This study is evaluating whether a combination of resveratrol, quercetin, and curcumin is safe and effective for people with age-related macular degeneration.
Eligible Conditions
- Age-Related Macular Degeneration
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Adverse Events
Change in Drusen Volume from Baseline
Geographic Atrophy (GA) Growth Rate
+1 moreSecondary study objectives
Progression to Advanced AMD
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Resveratrol, Quercetin, Curcumin (RQC)Experimental Treatment1 Intervention
Resveratrol (100mg BID), Quercetin (120mg BID), Curcumin (1000mg BID); 24 months
Group II: CurcuminActive Control1 Intervention
Curcumin (1000mg BID); 24 months
Find a Location
Who is running the clinical trial?
Paul A Knepper, MD PhDLead Sponsor
Paul A Knepper, MD, PhDPrincipal InvestigatorZaparackas Knepper, Ltd
1 Previous Clinical Trials
200 Total Patients Enrolled
Zibute Zaparackas, MDPrincipal InvestigatorZaparackas Knepper, Ltd
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger